2-(Trimethylsiloxy)phenyl isocyanide ( 1 ) reacts at −60 °C with triphenylborane to form the isocyanide adduct (2-(trimethylsiloxy)phenyl isocyanide)−triphenylborane ( 2 ). Upon desilylation in MeOH with a catalytic amount of KF at −30 °C 2 is converted into the ylidene adduct (1,2-dihydrobenzoxazol-2-ylidene)−triphenylborane ( 3 ). The X-ray crystal structures of 2 and 3 are reported. When it is heated, 2 dimerizes to give 1,4-bis(2-(trimethylsiloxy)phenyl)-2,2,3,5,5,6-hexaphenyl-2,5-dibora-2,5-dihydropyrazine ( 4 ). Si−O bond cleavage leads to 1,4-bis(2-hydroxyphenyl)-2,2,3,5,5,6-hexaphenyl-2,5-dibora-2,5-dihydropyrazine ( 5 ). Attempts to induce formation of a boron-bridged diylidene complex via attack of the hydroxyl oxygens in 5 at the pyrazine carbon atoms failed. Instead, complex 6, containing one bridging N,O-ylidene ligand, was obtained by partial hydrolysis of 5 . The molecular structure of 6, which crystallizes with one molecule of methanol and acetone each per formula unit, is reported.
No takes yet. Share an insight, caveat, or question.
Tamm et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: